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Abstract
Background: Second-generation intravenous blood-pool ultrasound contrast agents are increasingly used in
endoscopic ultrasound (EUS) for characterization of microvascularization, differential diagnosis of benign and
malignant focal lesions, as well as improved staging and guidance of therapeutic procedures.
Methods: The aim of our study was to prospectively compare the vascularisation patterns in chronic
pseudotumoral pancreatitis and pancreatic cancer using quantitative low mechanical index (MI) contrast-enhanced
EUS. We included 51 patients with chronic pseudotumoral pancreatitis (n = 19) and pancreatic cancer (n = 32).
Perfusion imaging started with a bolus injection of Sonovue (2.4 ml), followed by analysis in the early arterial (wash-in)
and late venous (wash-out) phase. Perfusion analysis was performed by post-processing of the raw data (time intensity
curve [TIC] analysis). TIC analysis was performed inside the tumor and the pancreatic parenchyma, with depiction of
the dynamic vascular pattern generated by specific software. Statistical analysis was performed on raw data extracted
from the TIC analysis. Final diagnosis was based on a combination of EUS-FNA, surgery and follow-up of minimum
6 months in negative cases.
Results: The sensitivity and specificity of low MI contrast enhanced EUS using TIC were sensitivity and specificity of low
MI contrast enhanced EUS using TIC analysis were 93.75% (95% CI = 77.77 - 98.91%) and 89.47% (95% CI = 65.46 - 98.15%),
respectively. Pseudotumoral chronic pancreatitis showed in the majority of cases a hypervascular appearance
in the early arterial phase of contrast-enhancement, with a dynamic enhancement pattern similar with the rest of
the parenchyma. Statistical analysis of the resulting series of individual intensities revealed no statistically relevant
differences (p = .78). Pancreatic adenocarcinoma was usually a hypovascular lesion, showing low contrast-enhancement
during the early arterial and also during the late venous phase of contrast-enhancement, also lower than the normal
surrounding parenchyma. We found statistically significant differences in values during TIC analysis (p < .001).
Conclusions: Low MI contrast enhanced EUS technique is expected to improve the differential diagnosis of focal
pancreatic lesions. However, further multicentric randomized studies will confirm the exact role of the technique and
its place in imaging assessment of focal pancreatic lesions.
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Background
Differentiating pancreatic adenocarcinoma from other
pancreatic masses remains still challenging with current
imaging techniques. Because histological assessment of
the pancreas is difficult in most of the cases, different
gold standards have been used to establish the
optimum number of EUS criteria for diagnosis of benign
or malignant disease [1].
Contrast Enhanced Harmonic Endoscopic Ultrasound
(CEH-EUS) was recently proposed as a suitable tool the
differential diagnosis of pseudotumoral chronic pancrea-
titis and pancreatic cancer, a new generation method
with high resolution [2,3]. Furthermore, it has the added
benefit of biological material sampling without risk of
tumor seeding. Assessment of tumor vascularity by
contrast enhanced EUS was limited until recently due
to the inability to use second-harmonic or pulse inversion
techniques, since EUS probes have high frequencies
from 5 to 12 MHz. Second generation contrast agents
and recent advances of new ultrasound systems now
allow better visualization of intralesional vascular
signals and indicate blood flow patterns of normal
and diseased tissue. Because it has a better resolution
than transabdominal ultrasound, CEH-EUS can thus
represent the best way to quantify the tumor vascula-
ture in a minimally invasive manner and with high
accuracy [2]. The European Union approved second-
generation contrast agent used in the most of the
examinations is SonoVue (Bracco SpA, Milan, Italy).
It contains phospholipid-stabilized microbubbles of
sulfur hexafluoride (SF6), which are stable and resistant
to pressure. Contrast microbubbles are restricted
inside of blood vessels and do not pass into the
extravascular compartment. They persist in the blood
until they are eliminated by the lungs in the expired
air [4].
The hypovascular aspect of the pancreatic lesions
under CEH-EUS seems to be highly sensitive and specific
for adenocarcinoma in several published studies [5,6].
Furthermore, the lesion size and margins are better
visualized, as well as the relationship with peripancreatic
arteries and veins. Focal lesions in chronic pseudotumoral
pancreatitis are reported to have similar or hyperenhance-
ment features as compared to the normal pancreatic
parenchyma [7].
Dynamic CEH-EUS techniques are particularly suitable
for measurement of focal lesions perfusion. Because
just visual appreciation can sometimes introduce diag-
nosis bias, there were described some computed post-
processing techniques (rise time and mean transit
time, peak intensity, and area under the curve etc.)
[4] which can accurately describe and calculate perfu-
sion parameters in order to appreciate the hyper- or
hypoenhancement pattern.
Methods
The aim of our study was to prospectively compare
the vascularization patterns in chronic pseudotumoral
pancreatitis and pancreatic cancer using quantitative
low mechanical index CEH-EUS.
We prospectively included all patients undergoing
CEH-EUS as part of the investigatory routine for either
chronic pancreatitis or pancreatic adenocarcinoma at the
Research Center of Gastroenterology and Hepatology of
Craiova. We excluded all patients with low quality exami-
nations (n = 3), thus resulting a total of 51 patients with
either chronic pseudotumoral pancreatitis (n = 19) or
pancreatic cancer (n = 32). Final diagnosis was based
on a combination of EUS-FNA, surgery and follow-up
of minimum 6 months in cytology or histology negative
cases. All patients signed informed consent forms and all
study procedures were in conformity with the Helsinki
Declaration, also receiving all necessary approvals from
the Ethic Committees of the University of Medicine and
Pharmacy of Craiova.
Patients were examined by two experienced examiners
(either AS or DIG). All the patients received propofol
sedation under the supervision of an anesthesiologist.
EUS examination equipment included a Hitachi Preirus
(Hitachi Medical Corp., Tokyo, Japan) ultrasound system
coupled with the EG 3830 linear endoscope (Pentax,
Hamburg, Germany). Perfusion imaging started with a
bolus injection of Sonovue (2.4 ml), followed by analysis
in the early arterial (wash-in) and late venous (wash-out)
phase. All the examinations were digitally recorded. All
image settings were maintained identical throughout the
investigations. We used a MI of 0.2 for all patients. The
examination ended with EUS-guided FNA, with 3 passes
performed. All Time intensity curve (TIC) analysis was
performed by trained personnel under their supervision
during offline post-processing, as described below. We
manually exported recordings of all contrast-enhanced
EUS procedures for each patient in uncompressed
audio-video interleaved (AVI) format at six frames per
seconds, for offline processing. Afterwards, movies were
loaded in the commercially available image processing
software Image Pro Plus (Media Cybernetics, USA) ver-
sion 7.0 in order to post-process the movies and perform
the TIC analysis. As full-frame, uncompressed .AVI files
were exported from the US machine, we did not encounter
any image artifacts. The software used for post-processing
equalized the brightness, contrast and gamma levels on a
frame-by-frame basis, thus linearizing the recording. We
then performed an automated frame-by-frame median
intensity tracking on two regions of interest (ROIs) – one
corresponding to the lesion, and one chosen from normal
surrounding parenchyma – obtaining TIC data in graphical
and numerical form. The TIC obtained for the normal ROI
was later set as reference track in the imaging software,
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thus obtaining relative values for the tumoral TIC as a
single data row. The whole lesion was taking into account
when selecting the corresponding ROI. We used an irregu-
lar shape to trace the contour of the lesion whenever
possible. Otherwise, we chose a significant portion of the
lesion (in several chronic pancreatitis cases). We selected a
circular area corresponding to healthy parenchyma, varying
it in size on a case-by-case basis, with a minimum radius
of 2 cm. The resulting data string was exported in
commercial spreadsheet software for plotting and statistical
analysis. We further indexed and performed basic
statistical analysis on the two sets of data. We calculated
peak intensities (Imax), time to peak (TTP) and area
under the curve (AUC) for the resulting track. As we
opted for a relative TIC representation, peak intensity for
the pancreatic adenocarcinoma TIC was considered the
absolute minimum intensity reached. The Mann–Whitney
non-parametric test was used for assessing the differences
between the enhancement patterns of the two pathologies,
as described by the consecutive intensities variances. P
values below 0.05 were considered significant.
Results
An overview of the most important parameters of our
study lot is presented in Table 1.
Overall, the sensitivity and specificity of low MI con-
trast enhanced EUS using TIC analysis were 93.75%
(95% CI = 77.77 - 98.91%) and 89.47% (95% CI = 65.46 -
98.15%), respectively. The positive predictive value of TIC
analysis was 93.75% (95% CI = 77.78 – 98.91%) and the
negative predictive value was 89.47% (95% CI = 65.46 –
98.15%). Positive diagnosis based only on TIC analysis was
achieved in 47 of the 51 patients, with two misdiagnosed
cases from each category.
TIC analysis parameters and features
By selecting the parenchymal ROI intensity track as
reference, we obtained a single relevant TIC as the dif-
ference between the two original ones. Results are
expressed as means and intervals in Table 2. Overall
median intensities of the two TICs were significantly dif-
ferent between the two groups (p < 0.0001) (Figure 1a).
We thus obtained a median Imax value of 11.4 for
pancreatic adenocarcinoma, compared to −54.1 for pan-
creatic adenocarcinoma ROIs (Mann-Withney p < 0.0001)
(Figure 1b). Time needed for the contrast agent varied for
both pathologies and was significantly lower in cases of
pseudotumoral pancreatitis compared to pancreatic adeno-
carcinoma (27.87 seconds versus 56.19 seconds, p < 0.0001)
(Figure 1c). AUC corresponding to pseudotumoral
pancreatitis TIC was also significantly lower from the AUC
of pancreatic adenocarcinoma TICs, as the intensities
reached were similar to the baseline parenchymal values
(p < 0.0001) (Figure 1d).
Chronic pseudotumoral pancreatitis
Unlike malignant tumors of the pancreas, focal mass-
forming pancreatitis had similar enhancement to that of
the normal surrounding parenchyma (Figure 2a and 2b).
Statistical analysis of the resulting series of individual
intensities revealed no statistically relevant differences
(p = 0.78) between the two ROIs, thus proving the
isoenhancing tendency. In 17 cases of pseudotumoral
chronic pancreatitis we could observe a hypervascular
appearance in the early arterial phase of contrast-enhance-
ment, with a dynamic enhancement pattern similar with
the rest of the parenchyma. The two cases with unusual
TIC representation showed marked hypoenhancement,
similarly to PA.
Pancreatic adenocarcinomas
A total of 30 pancreatic adenocarcinomas showed low
contrast enhancement in both arterial and in late phases,
characteristic to hypovascular lesions (Figure 3a and 3b).
The remaining two cases showed initial hyper enhance-
ment followed by rapid depletion of contrast agent then
stabilization near to parenchyma values. In all other
investigations, Mann–Whitney comparison of the two
series of values corresponding to the tumoral and
parenchyma ROIs showed statistically relevant differences
between the two TICs (p < 0.001).
Discussion
Differentiation of pseudotumoral pancratitis and pan-
creatic adenocarcinoma by imagistic methods has always
been difficult [8,9]. Inflammatory masses present in
chronic pancreatitis, called ‘pseudotumoral pancreatitis”
show similar aspects during CT and MRI evaluations,
thus other imaging techniques were proposed for inves-
tigating the pancreatic pathology [10]. CEH-EUS can
provide essential information regarding pancreatic
masses, as it can distinguish between different vascular
Table 1 Overview of the most important studied parameters
Women (%) Age (interval) Signal intensity compared to
parenchyma on entire TICs (interval)
Correct TIC-based diagnosis (%)
Pseudotumoral pancreatitis 12 (63) 45 (32 –73) 2.7 (0.8 – 6.9) 17 (89.5)
Pancreatic adenocarcinoma 14 (44) 53 (41 – 82) −18.4 (−30.1 – 0.17) 30 (93.75)
Mean age and gender repartition in each studied pathology. Median signal intensities for pseudotumoral pancreatitis and pancreatic adenocarcinoma resulting
TICs. Number of correct classifications based on TIC analysis only.
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patterns specific to each tumor. This greatly aids the
differential diagnostic efforts of the physician before
submitting the patient to more invasive investigations
such as fine needle EUS aspiration. This in turn greatly
improves the chances of targeted surgical interventions
where needed, earlier and at lower costs. It is currently
acknowledged that pancreaticoduodenectomy or other
major pancreatic surgeries are still associated with impor-
tant morbidity, with mortality rates ranging from 5 to 10%
in specialized centers [11-13], with even higher numbers
in smaller referral centers [11].
Several advantages of CEUS over CT and MRI exami-
nations can be identified. First of all, it can be performed
immediately, without any preliminary laboratory testing.
It operates in real time so that rapid changes in enhance-
ment can be observed and quantified. The US contrast
media are not nephrotoxic, do not interact with the thyroid
gland and anaphylactoid reactions are extremely rare [14].
The incidence of severe hypersensitivity or anaphylactoid
reactions is lower than with current X-ray agents [15].
The mechanical index is an important parameter that
influences microbubble behavior in contrast ultrasound
imaging.
High mechanical index procedure in conjunction with
contrast agents was initially used as color or power Doppler
signal enhancement technique. One of the main disadvan-
tages is the presence of artifacts, including flash and
blooming artifacts. Furthermore they strongly disrupt and
dissolve the microbubbles [4]. The new ultrasound systems
use contrast-specific software modes and low mechanical
index examination (between 0.08 and 0.3). CEH-EUS is a
relatively new method with accepted superiority over the
high mechanical index US and EUS [16].
The contrast enhanced ultrasound technique has some
limitations: 10% of the pancreatic carcinomas are hyper-
vascularised and in some cases of chronic pseudotumoral
Table 2 Mean maximum signal strengths, times to peak and areas under the curve calculated for the resulting TIC
Imax (interval) TTP (interval) AUC (interval)
Pseudotumoral pancreatitis 11.4 (3.8 – 12.9) 27.87 (20.4 – 36.9) 3627 (1247 – 5891)
Pancreatic adenocarcinoma −54.01 (−90.1 – 6.2) 56.19 (48.6 – 64.1) 24490 (14322 – 33789)
Imax =maximum intensity, expressed as arbitrary units; TTP = time to peak, expressed in seconds; AUC = area under the curve, expressed as a.u*seconds.
Figure 1 Statistical distribution of TIC-related parameters within the two lots. (a) Distribution of median intensities between the two
pathologies. (b) Distribution of the maximum intensities within the two lots. (c) Median times to peak for the two pathologies. (d) Area under the
curve for the two corresponding TICs. Legend: a.u. = arbitrary units; CP = chronic pancreatitis; PA = pancreatic adenocarcinoma; Imax =maximum
intensity; TTP = time to peak; AUC = area under the curve.
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pancreatitis areas of necrosis induces clear artifacts due to
lack of enhancing. These important limitations suggest that
a combination of non-invasive methods (CEH-EUS, EUS
elastography) can increase the accuracy of the diagnosis.
Second generation ultrasound micro-bubble contrast
agents such as Sonovue showed superior safety profiles to
CT or MRI contrast agents [14]. Their wide availability,
relatively low costs and virtually non-existing contraindi-
cations makes them extremely useful in both external
applications such as Contrast-Enhanced trans-abdominal
Ultrasound (CEUS) and contrast-enhanced EUS. However,
visual assessment remains subjective to the experience of
the investigator, as his impression on brightness and con-
trast variations are relative and cannot be compared to
other subsequent investigations. Thus, the need for accu-
rate quantification of perfusion patterns in tumor masses
rose from the necessity of better characterizing lesions
and unifying investigatory results.
In our study, we investigated, for the first time as far as
we know, the usefulness of time intensity curve (TIC) ana-
lysis in CEH-EUS application for the imaging of pan-
creatic adenocarcinoma and pseudotumoral pancreatitis.
The presented method proved to be efficient in differenti-
ating the two pathologies, correctly diagnosing a total of
47 cases out of the total of 51. Two cases were misdiag-
nosed from each pathology, showing superior accuracy in
recognizing malignant masses. We obtained a sensitivity
of 93.75% and specificity of 89.47% for TIC-based analysis
alone. Various studies showed high sensitivity values for
CEUS compared to CT when differentiating between pan-
creatic adenocarcinoma and pseudotumoral pancreatitis,
with sensitivities between 94% and 98% and accuracies as
high as 100% [17-19].
Our method implied the use of a versatile, commer-
cially available software for quantifying perfusion data,
followed by statistical analysis. Since the software was
Figure 2 Example of CEH-EUS and TIC of pseudotumoral chronic pancreatitis. (a) Pseudotumoral chronic pancreatitis. (b) Graphical
representation of the TIC trend line for the ROI corresponding to the inflammatory mass referenced to the parenchyma baseline.
Figure 3 Example of CEH-EUS and TIC of pancreatic adenocarcinoma. (a) Pancreatic adenocarcinoma. (b) Graphical representation of the TIC
trend line for the ROI corresponding to the tumor referenced to the parenchyma baseline.
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not specifically designed for TIC analysis, it may lack
immediate clinical application; however, in our study,
using its built-in automation ability, we could simplify
the processing, once the operator selected the two ROIs.
The statistical analysis was also automated through the
use of external scripting, greatly reducing the time
needed for the comparison, to 5 ± 2 minutes.
The quantification software provided measurements in
arbitrary units, as median frame intensity for each frame
of the AVI movie loaded. We opted for an offline quanti-
fication solution as it allows the processing of virtually
any investigation, as long as it is provided in a popular
digital movie format. This approach also permitted us to
semi-automate the process of plotting the TICs and
exporting raw numerical data to external spreadsheets,
by taking advantage of the extensive macro abilities built
in the software.
One element of novelty in our study was the attempt
to statistically analyse the differences between the two
raw data streams obtained before referencing the tracks
between them. Paired analysis between the tumoral ROI
and the corresponding parenchymal ROI thus revealed
statistically relevant differences in pancreatic adenocar-
cinoma cases, due to the low vascularity and consecutively
divergent curves obtained, compared to similar uptake
patterns in pseudotumoral pancreatitis cases, resulting
in minimal differences between the two rows of
values (p = 0.78).
When selecting intensity-related parameters, we opted
for expressing TICs as relative to one another. Hence,
we considered the parenchymal ROI as “reference track”
and expressed the mass-related TIC by subtracting the
values, thus obtaining a single TIC which better reflected
the variation in maximum intensities and times to reach
peaks and were better suited for the comparison of areas
under the curves. We obtained low negative values for
pancreatic adenocarcinomas (with a maximum low value
of −90.1 and a mean of 54.01), compared to values closer
to the reference track for pseudotumoral pancreatitis.
This is mainly due to the low vascularization of adeno-
carcinomas, which is severely decreased due to morpho-
logical changes at tumoral level [20]. A similar decrease
in vascularity is sometimes encountered in pancreatitis
lesions, due to increased fibrosis and the reorganization
of the tissue. However, the contrast agent can still achieve
similar perfusion levels to surrounding parenchyma, as
opposed to the neovascularization specific to pancreatic
cancers [10,21]. This visible decrease in contrast uptake is
considered by many authors to be the hallmark feature of
pancreatic adenocarcinomas, used to differentiate them
from pancreatitis masses [3-5,22].
Another advantage of using the referenced approach
in describing TICs was represented by the possibility
of calculating the time necessary to reach the peak
difference in signal, which, for adenocarcinomas, was
the time when the parenchyma had the highest value
when compared to the tumoral ROI. Our values were
somewhat similar to those reported by Kersting et al.
during CEUS investigations, in which significantly
more time passed before peak intensities were reached in
pancreatic ductal carcinomas [10].
AUC expresses the differences in amounts of contrast
flowing during the investigation in the two specified
ROI, as an integral of the sum of median maximum
frame intensities, since we calculated the AUC for the
reference curves obtained. Hence, we obtained signifi-
cantly lower AUC for pseudotumoral pancreatitis in
which the contrast uptake was similar to that in the
healthy pancreas reference ROI, while obtaining a much
higher AUC in cases with pancreatic adenocarcinomas.
Previous published studies clearly clarified that pancreatic
adenocarcinoma is a hypovascular tumor, although more
than 65% of the patients have detectable vessels inside
[19,23] Undifferentiated pancreatic tumors might become
hypervascular during the natural evolution, thus compli-
cating the differential diagnosis. This situation can be
overcome adding another non-invasive technique
performed in the same EUS examination which can
accurately predict the diagnosis – the real time EUS
elastography. To the best of our knowledge, the com-
bination of both methods performed during the same
EUS examination has not been tested in large multicentric
studies. EUS elastography had already be confirmed
as an important non-invasive diagnostic tool in an
European multicenter study [24,25]. Recent data on
the usefulness of CELMI EUS in comparison with
CEHMI EUS found higher sensitivity and specificity
for the latter (84.2% and 76.9% versus 89.5% and
92.3%, respectively) [2]. A combination between the
two techniques and a third, either elastography or
standard B-mode US, did not yield higher diagnostic
rates. One similar study combining information pro-
vided by contrast enhanced color Doppler EUS and
EUS elastography [5] showed specificity and predictive
positive values higher than 95%, indicating a high pre-
dictability of malignancy in these patients. Although
this combination of the methods will not reduce the
need for EUS-FNA, it does raise the possibility of re-
ferring patients directly for surgery in the presence of
resectable focal masses.
Conclusions
In conclusion, CEH–EUS is a promising method that per-
mits a better differentiation of focal pancreatic masses. As
future applications, it can surely be used for patients’
follow-up during chemotherapy or anti-angiogenic treat-
ment. One possible limitation of our study would be the
relatively low number of patients included. Even so, the
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strength of the study in offered by computed analysis of
the recorded movies with no human bias introduced and
no subsequent knowledge about patients’ history of the
doctor selecting the ROI (C.T.S.). Considering the inclu-
sion of the patients belonging of a single tertiary center,
large European multicentric studies with adequate power
are needed in order to validate the method.
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